Didem Atay

Prof. Didem Atay

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Turkish Journal of Hematology
Verified
Journal Article
Open access
YAYesim Aydinok
Yesim Aydinok
YOYeşim Oymak
Yeşim Oymak
BABerna Atabay
Berna Atabay
GAGönül Aydoğan
Gönül Aydoğan
AYAkif Yeşilipek
Akif Yeşilipek
ZKZeynep Karakaş
Zeynep Karakaş
The Turkish Society of Pediatric Hematology set up a National Hemoglobinopathy Registry to demonstrate the demographic and disease characteristics of patients and assess the efficacy of a hemoglobinopathy control program (HCP) over 10 years in Turkey. A total of 2046 patients from 27 thalassemia centers were registered, of which 1988 were eligible for analysis. This cohort mainly comprised patients with β-thalassemia major (n=1658, 83.4%) and intermedia (n=215, 10.8%). The majority of patients were from the coastal areas of Turkey. The high number of patients in Southeastern Anatolia was due to that area having the highest rates of consanguineous marriage and fertility. The most common 11 mutations represented 90% of all β-thalassemia alleles and 47% of those were IVS1-110(G->A) mutations. The probability of undergoing splenectomy within the first 10 years of life was 20%, a rate unchanged since the 1980s. Iron chelators were administered as monotherapy regimens in 95% of patients and deferasirox was prescribed in 81.3% of those cases. Deferasirox administration was the highest (93.6%) in patients aged <10 years. Of the thalassemia major patients, 5.8% had match-related hemopoietic stem cell transplantation with a success rate of 77%. Cardiac disease was detected as a major cause of death and did not show a decreasing trend in 5-year cohorts since 1999. While the HCP has been implemented since 2003, the affected births have shown a consistent decrease only after 2009, being at lowest 34 cases per year. This program failure resulted from a lack of premarital screening in the majority of cases. Additional problems were unawareness of the risk and misinformation of the at-risk couples. In addition, prenatal diagnosis was either not offered to or was not accepted by the at-risk families. This study indicated that a continuous effort is needed for optimizing the management of thalassemia and the development of strategies is essential for further achievements in the HCP in Turkey.

1 August 2011 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
DADidem Atay
Didem Atay
GOGulyuz Ozturk
Gulyuz Ozturk
AAArzu Akcay
Arzu Akcay
MYMelek Msc Yanasik
Melek Msc Yanasik
SASema Anak
Sema Anak
ODOmer Devecioglu
Omer Devecioglu
Background Despite the introduction of new broad-spectrum antibiotics and antifungal therapies over the past decade, infections remains the most frequent cause of death in patients with neutropenia. The aim of this study is to assess the effect and safety of granulocyte transfusions (GTX) for the treatment of severe life-threatening infections in pediatric patients with febrile neutropenia or defective granulocyte functions. Methods In this study, 35 pediatric patients with high-risk febrile neutropenia or defective granulocyte functions, who received 111 GTX, were included. GTX were used for 3 consecutive days during infections not responding to antimicrobial therapy. Results The mean granulocyte content per concentrate was 27.4×109 (min: 4.2×109 to max: 68.4×109) depending on donor's white blood cell count before harvest. GTX were well tolerated in all patients. The infection-related survival rate was 82.4% and overall survival rate was 77.1% at day 30. The overall survival rate was 65.7% and 52% at 3 and 48 months, respectively. Conclusions GTX is safe and effective in controlling the life-threatening infections. Further randomized controlled studies with long-term follow-up are needed to assess the exact role of GTX in the outcome of patients with neutropenia and patients with defective granulocyte functions.

9 February 2010 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
SASema Anak
Sema Anak
DADidem Atay
Didem Atay
AUAysegul Unuvar
Aysegul Unuvar
MGMesut Garipardic
Mesut Garipardic
LALeyla Agaoglu
Leyla Agaoglu
ODOmer Devecioglu
Omer Devecioglu

13 December 2015 in Stem Cells International
Verified
Journal Article
Open access
PDF file
FEFatih Erbey
Fatih Erbey
DADidem Atay
Didem Atay
AAArzu Akcay
Arzu Akcay
EOErcument Ovali
Ercument Ovali
GOGulyuz Ozturk
Gulyuz Ozturk
This study evaluated the efficacy of mesenchymal stem cells (MSCs) from bone marrow of a third‐party donor for refractory aGVHD. We report the first experience using MSCs to treat refractory aGVHD in 33 pediatric patients undergoing allogeneic HSCT from Turkey. Totally, 68 doses of bone marrow derived MSCs were infused. The median dose of MSC was 1.18 × 106 cells per kg body weight. Overall, complete response (CR) was documented in 18 patients, partial response (PR) was documented in 7 patients, and no response (NR) was documented in 8 patients. The 2‐year estimated probability of overall survival (OS) for patients achieving CR and PR/NR was 63.8% and 29.4%, respectively (p = 0.0002). While the cumulative incidence of transplant related mortality (TRM) at day 100 after first MSC infusion was 46.6% in PR/NR patients, there was no any TRM at day 100 after first MSC infusion in CR patients (p = 0.001). Twelve patients developed chronic GVHD (cGVHD); eight of them were alive, with five having extensive disease and three having limited disease. In conclusion, MSCs appear to be safe and effective treatment option for pediatric patients with steroid refractory aGVHD. But the efficacy of MSCs on cGVHD in aGVHD patients treated with MSCs seems to be limited.

3 January 2018 in Pediatric Transplantation
Verified
Journal Article
Open access
PDF file
DADidem Atay
Didem Atay
AAA. Akcay
A. Akcay
FEF. Erbey
F. Erbey
GOG. Ozturk
G. Ozturk
Viral infections remain one of the most important complications following allogeneic HSCT. Few reports compare virus infection between different donor types in pediatric patients. We retrospectively analyzed viral infections and the outcome of one hundred and seventy‐one pediatric patients (median 7.38 years) who underwent allogeneic HSCT from matched related donor (MRD, n = 71), 10 of 10 HLA allele‐matched unrelated donors (MUD1; n = 29), 9 of 10 HLA allele‐matched unrelated donors (MUD2; n = 40), and haploidentical donors (n = 31). PCR screening for BK virus, adenovirus, Epstein‐Barr virus, parvovirus B19, human herpesvirus 6, and CMV were performed routinely weekly. Infections between 0‐30, 31‐100, and 101 days‐2 years were identified separately. BK virus and CMV reactivations were significantly low in MRD transplant patients (P = .046 and P < .0001, respectively), but incidences of all virus infections between MUD1, MUD2, and haplo‐HSCT were found statistically not different. The OS was found to be affected by having one or multiple virus infection (P = .04 and P = .0008). Despite antiviral prophylaxis and treatments, post‐transplant viral infections are associated with reduced overall survival. Haplo‐HSCT is comparable with MUD transplantation in the setting of viral infections. A larger study group and prospective studies are needed to confirm this observation.

20 May 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ODOmer Devecioglu
Omer Devecioglu
SASema Anak
Sema Anak
DADidem Atay
Didem Atay
PAPinar Aktan
Pinar Aktan
EDEsra Devecioglu
Esra Devecioglu
ESEbru Saribeyoglu
Ebru Saribeyoglu